Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Nanologica AB's annualizedNet Income for the quarter that ended in Mar. 2026 was €24.21 Mil. Nanologica AB's average total tangible assets for the quarter that ended in Mar. 2026 was €15.40 Mil. Therefore, Nanologica AB's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 157.18%.
The historical rank and industry rank for Nanologica AB's Return-on-Tangible-Asset or its related term are showing as below:
FRA:4YD'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -93.38 Med: -62.33 Max: 19.86
Current: 19.86
During the past 12 years, Nanologica AB's highest Return-on-Tangible-Asset was 19.86%. The lowest was -93.38%. And the median was -62.33%.
FRA:4YD's Return-on-Tangible-Asset is ranked better than 95.34% of 1415
companies
in the Biotechnology industry
Industry Median: -36.15
vs FRA:4YD: 19.86
Nanologica AB (FRA:4YD) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Nanologica AB Return-on-Tangible-Asset Related Terms
Nanologica AB Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Nanologica AB's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4YD vs VRTX, REGN, RVMD: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Nanologica AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanologica AB Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanologica AB's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Nanologica AB's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 157.18% mean?
Nanologica AB (FRA:4YD) has a Return-on-Tangible-Asset of 157.18% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Nanologica AB and its competitors. According to the industry distribution chart, Nanologica AB ranks #66 out of 1415 companies in the Biotechnology industry, placing it in the top 4.7%.
Is Nanologica AB's Return-on-Tangible-Asset too high?
Nanologica AB's current Return-on-Tangible-Asset is 157.18%. Based on the distribution chart, Nanologica AB ranks #66 out of 1415 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Nanologica AB has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Nanologica AB's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanologica AB ranks #66 out of 1415 companies for Return-on-Tangible-Asset. This places Nanologica AB in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Nanologica AB and its competitors. Nanologica AB's current Return-on-Tangible-Asset is 157.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanologica AB stock overvalued right now?
Nanologica AB (FRA:4YD) has a current Return-on-Tangible-Asset of 157.18%. The stock's GF Value™ is €0.30, compared to a current price of €0.03 — trading 89.2% below its estimated fair value. The current Return-on-Tangible-Asset is 157.18%. Nanologica AB's overall GF Score™ is 46/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Nanologica AB (FRA:4YD), the current Return-on-Tangible-Asset is 157.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanologica AB (FRA:4YD) Overvalued in 2026?
Based on GuruFocus' analysis, Nanologica AB stock appears to be undervalued.
The current stock price of €0.03 is trading 89.2% below its estimated GF Value™ of €0.30.
Key valuation signals for FRA:4YD:
Return-on-Tangible-Asset: 157.18%
GF Value™: €0.30 vs. price of €0.03 (89.2% below fair value)
No single metric tells the full story. See the FRA:4YD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells key consumables to pharmaceutical manufacturers. Its products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, it can increase productivity and reduce costs for pharmaceutical manufacturers. The group operates in a world-wide niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
46GF Score
Get the complete analysis for FRA:4YD
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4YD has been successfully added to your 
